Clinical Trial Update: Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects [Phase 3]

View source ↗

Summary

Phase 3 non-inferiority trial comparing a meningococcal vaccine GSK134612 to Mencevax in children aged 2-10; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GSK134612 (Meningococcal vaccine)
• Mencevax

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal, Meningococcal Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2017-10-06